Faculty profile

Nathalie Johnson

ResearcherMedicineMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.

Nathalie Johnson

Researcher

Medicine

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
8 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2017.
Supervised 1 trainee who won CIHR awards, most recently in 2017.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Lymphoma Sequencing Circulating Tumour Dna Dlbcl Follicular Lymphoma Hodgkin Immunotherapy Jak/Stat

Latest papers

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).
Blood neoplasia · 2026
A longitudinal study of research productivity in McGill University's MD-PhD and Clinician Investigator Program Graduates from 2000 to 2017.
Clinical and investigative medicine. Medecine clinique et experimentale · 2026
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
EBioMedicine · 2024

All 16 publications

Latest funding

Understanding the role of the MNK/eIF4E axis in cells of the tumor microenvironment to improve outcomes for patients with DLBCL.
CIHR · 2024 · Co-investigator
$1,090,125
Optimizing immunotherapy in high-risk lymphoma
CIHR · 2017 · Nominated PI
$1,208,700
Optimizing Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma
CIHR · 2017 · Supervisor
$5,000

All 5 grants and awards

16 publications.

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Assouline S, Prica A, Villa D, Kridel R, Johnson N, Kukreti V, Shamy A, Kaedbey R, Gerrie A, Savage K, Kelly J, Shepherd LE, Hay AE, Scott DW, Crump M, Chen BE, Kuruvilla J

Blood neoplasia2026

DOI: 10.1016/j.bneo.2026.100233 PMID: 42255257

A longitudinal study of research productivity in McGill University's MD-PhD and Clinician Investigator Program Graduates from 2000 to 2017.

Magrill J, Falet JP, Boone E, Luigi M, Arthur I, Asadi P, Frumkin A, Sorin M, Romero JM, Luo J, Johnson N, Eisenberg MJ

Clinical and investigative medicine. Medecine clinique et experimentale2026

DOI: 10.3138/cim-2026-0009 PMID: 42446907

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

MacManus MP, Seymour JF, Tsang H, Fisher R, Keane C, Sabdia MB, Law SC, Gunawardana J, Nath K, Kazakoff SH, Marques-Piubelli ML, Duenas DE, Green MR, Roos D, O'Brien P, McCann A, Tsang R, Davis S, Christie D, Cheah C, Amanuel B, Cochrane T, Butler J, Johnston A, Shanavas M, Li L, Vajdic C, Kridel R, Shelton V, Hershenfield S, Baetz T, Lebrun D, Johnson N, Brodtkorb M, Ludvigsen M, d'Amore F, Thompson ER, Blombery P, Gandhi MK, Tobin JWD

EBioMedicine2024

DOI: 10.1016/j.ebiom.2024.105468 PMID: 39631145

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.

Hershenfeld SA, Tobin JWD, Shelton V, Calvente L, Lajkosz K, Liu T, Brodtkorb M, d'Amore FA, Ludvigsen M, Baetz T, LeBrun D, Johnson N, Crump M, Hong M, Kuruvilla J, Tremblay-LeMay R, MacManus M, Tsang R, Hodgson DC, Gandhi MK, Kridel R

British journal of haematology2024

DOI: 10.1111/bjh.19698 PMID: 39112220

Analysis by TeloView® Technology Predicts the Response of Hodgkin's Lymphoma to First-Line ABVD Therapy.

Knecht H, Johnson N, Bienz MN, Brousset P, Memeo L, Shifrin Y, Alikhah A, Louis SF, Mai S

Cancers2024

DOI: 10.3390/cancers16162816 PMID: 39199588

Fine Needle Aspirate Flow Cytometry's Ancillary Utility in Diagnosing Non-Hodgkin Lymphoma in the Head and Neck.

Bandargal S, Florianova L, Dmitrienko S, Haliotis T, Pusztaszeri MP, Hier MP, Mlynarek AM, Mascarella MA, Payne RJ, Daniela da Silva S, Johnson N, Forest VI

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2024

DOI: 10.1177/19160216241296127 PMID: 39511788

Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.

Owen C, Eisinga S, Banerji V, Johnson N, Gerrie AS, Aw A, Chen C, Robinson S

Leukemia research2023

DOI: 10.1016/j.leukres.2023.107372 PMID: 37633157

Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma.

Petrogiannis-Haliotis T, Pehr K, Roberge D, Rys RN, Monczak Y, Popradi G, Ajjamada L, Benlimame N, Querfeld C, Johnson N, Knecht H

Biomedicines2023

DOI: 10.3390/biomedicines11020634 PMID: 36831170

Erratum: The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

Safavi S, Larouche A, Zahn A, Patenaude AM, Domanska D, Dionne K, Rognes T, Dingler F, Kang SK, Liu Y, Johnson N, Hébert J, Verdun RE, Rada CA, Vega F, Nilsen H, Noia JMD

NAR cancer2021

DOI: 10.1093/narcan/zcaa045 PMID: 34316697

The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

Safavi S, Larouche A, Zahn A, Patenaude AM, Domanska D, Dionne K, Rognes T, Dingler F, Kang SK, Liu Y, Johnson N, Hébert J, Verdun RE, Rada CA, Vega F, Nilsen H, Di Noia JM

NAR cancer2020

DOI: 10.1093/narcan/zcaa019 PMID: 33554121

Something wrong or missing on this profile? Suggest a correction

Nathalie Johnson

Research

Latest papers

Latest funding

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

A longitudinal study of research productivity in McGill University's MD-PhD and Clinician Investigator Program Graduates from 2000 to 2017.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.

Analysis by TeloView® Technology Predicts the Response of Hodgkin's Lymphoma to First-Line ABVD Therapy.

Fine Needle Aspirate Flow Cytometry's Ancillary Utility in Diagnosing Non-Hodgkin Lymphoma in the Head and Neck.

Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.

Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma.

Erratum: The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

Understanding the role of the MNK/eIF4E axis in cells of the tumor microenvironment to improve outcomes for patients with DLBCL.

Optimizing immunotherapy in high-risk lymphoma

Optimizing Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Investigating the mutations driving non Hodgkin lymphomas and developing plasma-based assays for tumour detection and monitoring

Overcoming therapeutic resistance in lymphoma

Frequent collaborators

Robert Kridel

John Kuruvilla

David Lebrun

Gerald Batist

Gerald Batist

Jiarui Ding

Mark Sorin

Versha Banerji

Michael Pollak

Ali Bashashati

Aly Karsan

Sabine Mai

Christian Steidl

Lawrence Panasci

Nathalie Johnson

Research

Latest papers

Latest funding

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

A longitudinal study of research productivity in McGill University's MD-PhD and Clinician Investigator Program Graduates from 2000 to 2017.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.

Analysis by TeloView&#xae; Technology Predicts the Response of Hodgkin's Lymphoma to First-Line ABVD Therapy.

Fine Needle Aspirate Flow Cytometry's Ancillary Utility in Diagnosing Non-Hodgkin Lymphoma in the Head and Neck.

Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.

Primary Cutaneous Multifocal Indolent CD8+ T-Cell Lymphoma: A Novel Primary Cutaneous CD8+ T-Cell Lymphoma.

Erratum: The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

Understanding the role of the MNK/eIF4E axis in cells of the tumor microenvironment to improve outcomes for patients with DLBCL.

Optimizing immunotherapy in high-risk lymphoma

Optimizing Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Investigating the mutations driving non Hodgkin lymphomas and developing plasma-based assays for tumour detection and monitoring

Overcoming therapeutic resistance in lymphoma

Frequent collaborators

Robert Kridel

John Kuruvilla

David Lebrun

Gerald Batist

Gerald Batist

Jiarui Ding

Mark Sorin

Versha Banerji

Michael Pollak

Ali Bashashati

Aly Karsan

Sabine Mai

Christian Steidl

Lawrence Panasci

Analysis by TeloView® Technology Predicts the Response of Hodgkin's Lymphoma to First-Line ABVD Therapy.